Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Immunogen Inc., 1globe Health Institute LLC

Conditions

Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.Platinum-sensitive epithelial ovarianfallopian tubeor primary peritoneal cancers

Phase 2

A Phase II/III Randomized, Open-Label Clinical Study of Napabucasin in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients with Metastatic Pancreatic Cancer Following Chemotherapy Failure

Active, not recruitingCTIS2024-518205-17-00

1globe Health Institute LLCHistologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.

Start: 2022-05-27Target: 84Updated: 2025-12-10

Phase 3

2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA).

RecruitingCTIS2022-501606-35-01

Immunogen Inc.fallopian tube, or primary peritoneal cancers, Platinum-sensitive epithelial ovarian

Start: 2024-02-21Target: 110Updated: 2026-01-21